ReviewBreast cancer research : BCR2014
Breast cancer intra-tumor heterogeneity.
Review in Breast cancer research : BCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
199 citing papers in PubMed, 2 syntheses or guidelines pooled it, 334 citations in OpenAlex.
- Artificial intelligence-assisted PET imaging for predicting neoadjuvant chemotherapy response in breast cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Pooled it
- Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer.International journal of nanomedicine · 2022Trial
- Neoantigens elicit T cell responses in breast cancer.Scientific reports · 2021Trial
- High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.Molecular oncology · 2021Trial
- PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer.International journal of molecular sciences · 2020Trial
- Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer.Molecular oncology · 2019Trial
- Article
- Single-Cell Analysis Reveals STARD10 as a Fatty Acid Metabolism Regulator of Breast Cancer Progression via the PI3K/Akt Pathway.International journal of molecular sciences · 2026Article
- Article
- Enhancing Translation of H&E to IHC with Robust Tumor-Infiltrating Lymphocytes Quantification Using Deep Generative Models: A Feasibility Study.Journal of imaging informatics in medicine · 2026Article
- Frequency Maps of FTIR Images for Phenotyping Molecular Heterogeneity of the Primary Tumor and Its Metastases.Analytical chemistry · 2026Article
- ALKBH4 confers ferroptosis resistance and drives tumorigenesis via dysregulation of GPX4 in breast cancer cells.In vitro cellular & developmental biology. Animal · 2026Article
- Review
- Integrative Raman Spectroscopy and Multi-Omics Analysis of Lipid and Matrix Protein Heterogeneity in Triple-Negative Breast Cancer.Chemical & biomedical imaging · 2026Article
- Single-cell analysis reveals that MXRA8 affected the progression of breast cancer via regulating ferroptosis.Cancer cell international · 2026Article
- AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery.Iranian journal of basic medical sciences · 2026Review
- Multimodal PA/US imaging and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers: A novel approach for targeted therapy selection.Photoacoustics · 2025Article
- Multi-gene expression assays in breast cancer: a literature review.Translational cancer research · 2025Review
- Diffraction-informed deep learning for molecular-specific holograms of breast cancer cells.APL bioengineering · 2025Article
139 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years it has become clear that cancer cells within a single tumor can display striking morphological, genetic and behavioral variability. Burgeoning genetic, epigenetic and phenomenological data support the existence of intra-tumor genetic heterogeneity in breast cancers; however, its basis is yet to be fully defined. Two of the most widely evoked concepts to explain the origin of heterogeneity within tumors are the cancer stem cell hypothesis and the clonal evolution model. Although the cancer stem cell model appeared to provide an explanation for the variability among the neoplastic cells within a given cancer, advances in massively parallel sequencing have provided several lines of evidence to suggest that intra-tumor genetic heterogeneity likely plays a fundamental role in the phenotypic heterogeneity observed in cancers. Many challenges remain, however, in the interpretation of the next generation sequencing results obtained so far. Here we review the models that explain tumor heterogeneity, the causes of intra-tumor genetic diversity and their impact on our understanding and management of breast cancer, methods to study intra-tumor heterogeneity and the assessment of intra-tumor genetic heterogeneity in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.